ICUs act as the hotbeds of bacterial resistance, with a highly susceptible population, prone to infection due to impaired defense mechanisms, and often requiring invasive interventions involving breach of anatomical barriers. The highest incidence of hospital-acquired infections occurs in ICUs (1). The high incidence of nosocomial infection, combined with widespread, often injudicious antibiotic use, results in… Continue reading Empirical antibiotic therapy: de-escalation demystified
Ventilator-associated pneumonia (VAP) caused by multidrug-resistant bacteria continues to be a major cause of morbidity and mortality in our ICUs. We have a limited choice of antibiotics to combat the resistant bacterial flora prevalent in many units. Besides, most systemically administered antibiotics fail to attain therapeutic concentrations in the lung. This has led many clinicians… Continue reading Is it the end of the road for inhaled antibiotics in ventilator-associated pneumonia?
The World Health Organization reported the emergence of omicron (B.1.1.529), the fifth SARS-CoV-2 variant of concern, on 25th November 2021.1 The first report of the omicron variant was from Botswana, followed by a case from Hong Kong. A steep rise in cases was observed in South Africa, especially from the Gauteng province in the ensuing… Continue reading The omicron variant: what do we know so far?
Background Non-invasive modalities of respiratory support are increasingly being employed in the management of acute hypoxemic respiratory failure in COVID-19, considering early reports that suggested high mortality with invasive mechanical ventilation.1 Respiratory support with high-flow nasal cannula (HFNC) has been found to be associated with reduced 90-day mortality in non-COVID-19-related acute hypoxemic respiratory failure.2 In a… Continue reading High-flow nasal cannula in COVID-19: the HiFLo-Covid randomized controlled trial￼
Something went wrong. Please refresh the page and/or try again.
Subscribe to My Blog
Get new content delivered directly to your inbox.